Select a medication above to begin.
Angeliq
drospirenone/ estradiol
Black Box Warnings .
Endometrial Cancer with Unopposed Estrogen in Patients with Intact Uterus
unopposed estrogen use incr. risk of endometrial CA in patients with intact uterus; adding progestogen has been shown to decr. risk of endometrial hyperplasia, a possible precursor to endometrial CA; perform adequate diagnostic measures (including directed or random endometrial sampling) to rule out malignancy in menopausal patient with abnormal genital bleeding of unknown etiology
Adult Dosing .
Dosage forms: TAB: 0.25 mg/0.5 mg, 0.5 mg/1 mg
vasomotor symptoms, moderate-severe menopausal
- [1 tab PO qd]
- Info: use lowest effective estrogen dose, shortest effective tx duration
vulvovaginal atrophy, moderate-severe menopausal
- [0.5 mg/1 mg PO qd]
- Info: use lowest effective estrogen dose, shortest effective tx duration; not preferred if local symptoms only
renal dosing
- [see below]
- renal impairment: contraindicated
- HD/PD: contraindicated
hepatic dosing
- [see below]
- hepatic impairment: contraindicated
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.